Palatin Technologies, Inc.
PTNHealthcareNASDAQBiotechnology · Last scanned Oct 23, 2026
Scan Results
Daily timeframePalatin Technologies, Inc., a biopharmaceutical company, develops first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system in the United States. Valued at $9.8M, PTN is a micro-cap name in its sector. It is developing oral small molecule PL7737 agonist in preclinical studies; long-acting peptide MC4R agonists; and Bremelanotide co-administration with Tirzepatide to treat obesity completed Phase 2 clinical trial; completed a phase 2 of diabetic nephropathy It also provides pl9643 for dry eye disease; and oral PL8177 for inflammatory bowel diseases.
Market Cap
$9.8M
Beta
-0.01
P/E (TTM)
—
P/E (Fwd)
-2.97
EPS (TTM)
$-2.96
EPS (Fwd)
$-1.85
ROE
-877.5%
ROA
-91.9%
Cash
$7.5M
Total Debt
$223,679
Free CF
-$10.7M
52W Change
-6.6%
Annual Financials
Cash vs Debt
Where PTN stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, PTN finished 54.66% below its 150-day moving average ($13.21) and 58.89% below its 200-day moving average ($14.57). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is PTN overbought or oversold?
At the October 20, 2026 close, PTN's RSI(14) was 15.8, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Palatin Technologies, Inc. holds $7.5M in cash against $224K in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. Free cash flow is running at -$10.7M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. ROE of -877.5% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has pulled back from $1.5M (2022) to $0 (2025), a 100% decline worth watching.
The relatively low beta of -0.01 suggests PTN is a less volatile holding compared to the broader index. The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing PTN.